SOPH
SOPHiA GENETICS SA
$5.00
+0.81%
$355.5M
No data for this timeframe.
Vol
Market Cap$355.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Insider Activity1B / 49S
Insider Net $-$792.7K
SEC Reports14
Exchange Nasdaq·Sector Services-Computer Processing & Data Preparation·Inc. V8·CIK 0001840706·Prev Close $4.96
Recent Activity
Jun 5, 2026
Insider
CARDOZA GEORGE bought 20,000 shares
Chief Financial Officer @ $4.95 ($99.0K)
Jun 4, 2026
SEC
SOPHiA GENETICS announced a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) to form
6-K — Impact 6/10
Jun 1, 2026
SEC
Seven SOPHiA GENETICS insiders, including the CEO and C-suite, sold a total of $57K in open-market sales over a 7-day wi
CLUSTER — Impact 3/10
May 26, 2026
Insider
Menu Philippe sold 5,000 shares
Chief Medical Officer @ $4.95 ($24.8K)
May 20, 2026
SEC
Four SOPHiA GENETICS insiders sold a total of $77K in shares over a 7-day window, representing 0.023% of the company's $
CLUSTER — Impact 2/10
May 19, 2026
Insider
Puylaert Kevin sold 33 shares
Chief Sales Officer @ $4.54 ($149.90)
May 5, 2026
earnings_calendar
SOPH Q1 2026 Earnings Scheduled — 2026-05-05
Price Targets
$8.00
+60.0% upside
Strong Buy
Current $5.00
Low $7.00
Median $8.00
High $9.00
3 analysts
$7.00
$9.00
Analyst Ratings
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | BTIG | REITERATE | Buy → Buy |
| Apr 15, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Jan 26, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.22 ▼ -4.8% | $-0.22 — $-0.22 | 10% YoY | 1 |
| Next Q | $-0.19 | $-0.19 — $-0.19 | 3% YoY | 1 |
| Current FY | $-0.78 ▲ +2.5% | $-0.78 — $-0.78 | 2% YoY | 1 |
| Next FY | $-0.56 | $-0.56 — $-0.56 | 28% YoY | 1 |
Latest Reports
BULLISH
6-K
6/10
SOPHiA GENETICS announced a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) to form
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Seven SOPHiA GENETICS insiders, including the CEO and C-suite, sold a total of $57K in open-market sales over a 7-day wi
Jun 1, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | CARDOZA GEORGE | BUY | $99.0K |
| May 26, 2026 | Menu Philippe | SELL | $24.8K |
| May 19, 2026 | Puylaert Kevin | SELL | $149.90 |
| May 19, 2026 | Van Well | SELL | $3.1K |
| May 19, 2026 | Valente Manuela | SELL | $1.7K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
10 unique insiders with 50 transactions. Net insider value: -$792.7K ($99.0K bought, $891.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | CARDOZA GEORGE | Chief Financial Officer | BUY | 20,000 | $4.95 | $99.0K |
| May 26, 2026 | Menu Philippe | Chief Medical Officer | SELL | 5,000 | $4.95 | $24.8K |
| May 19, 2026 | Puylaert Kevin | Chief Sales Officer | SELL | 33 | $4.54 | $149.90 |
| May 19, 2026 | Van Well Daan | Chief Legal Officer | SELL | 684 | $4.60 | $3.1K |
| May 19, 2026 | Valente Manuela | Chief People Officer | SELL | 380 | $4.60 | $1.7K |
| May 19, 2026 | Menu Philippe | Chief Medical Officer | SELL | 608 | $4.61 | $2.8K |
| May 19, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 608 | $4.60 | $2.8K |
| May 19, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 4,486 | $4.60 | $20.7K |
| May 19, 2026 | Muken Ross | President | SELL | 761 | $4.60 | $3.5K |
| May 13, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 4,000 | $4.54 | $18.2K |
| May 12, 2026 | HIBBS KATHY L | Director | SELL | 7,508 | $4.67 | $35.0K |
| May 12, 2026 | Menu Philippe | Chief Medical Officer | SELL | 5,000 | $4.67 | $23.3K |
| May 11, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 8,500 | $5.09 | $43.2K |
| Apr 27, 2026 | Menu Philippe | Chief Medical Officer | SELL | 5,000 | $4.82 | $24.1K |
| Apr 20, 2026 | Muken Ross | President | SELL | 760 | $5.20 | $4.0K |
| Apr 20, 2026 | Puylaert Kevin | Chief Sales Officer | SELL | 33 | $5.08 | $167.69 |
| Apr 20, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 4,486 | $5.21 | $23.3K |
| Apr 20, 2026 | Menu Philippe | Chief Medical Officer | SELL | 608 | $5.20 | $3.2K |
| Apr 20, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 608 | $5.21 | $3.2K |
| Apr 20, 2026 | Valente Manuela | Chief People Officer | SELL | 380 | $5.20 | $2.0K |
| Apr 20, 2026 | Van Well Daan | Chief Legal Officer | SELL | 684 | $5.20 | $3.6K |
| Apr 15, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 17,473 | $5.00 | $87.4K |
| Apr 14, 2026 | Muken Ross | President | SELL | 2,800 | $4.96 | $13.9K |
| Apr 14, 2026 | Menu Philippe | Chief Medical Officer | SELL | 1,600 | $4.96 | $7.9K |
| Apr 14, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 43,129 | $4.96 | $213.8K |
| Apr 14, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 600 | $4.97 | $3.0K |
| Apr 13, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 4,399 | $4.76 | $21.0K |
| Apr 13, 2026 | Muken Ross | President | SELL | 4,442 | $4.77 | $21.2K |
| Apr 13, 2026 | Menu Philippe | Chief Medical Officer | SELL | 1,000 | $4.76 | $4.8K |
| Apr 13, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 1,014 | $4.76 | $4.8K |
| Apr 10, 2026 | Van Well Daan | Chief Legal Officer | SELL | 2,400 | $4.67 | $11.2K |
| Apr 10, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 8,500 | $4.72 | $40.1K |
| Apr 10, 2026 | Menu Philippe | Chief Medical Officer | SELL | 3,725 | $4.68 | $17.4K |
| Apr 10, 2026 | Muken Ross | President | SELL | 3,687 | $4.69 | $17.3K |
| Apr 10, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 3,706 | $4.68 | $17.3K |
| Apr 9, 2026 | Van Well Daan | Chief Legal Officer | SELL | 1,988 | $4.74 | $9.4K |
| Apr 9, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 1,950 | $4.74 | $9.2K |
| Apr 9, 2026 | Menu Philippe | Chief Medical Officer | SELL | 1,931 | $4.74 | $9.2K |
| Apr 9, 2026 | Muken Ross | President | SELL | 1,950 | $4.74 | $9.2K |
| Apr 9, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 1,936 | $4.74 | $9.2K |
| Apr 8, 2026 | CARDOZA GEORGE | Chief Financial Officer | SELL | 1,403 | $4.85 | $6.8K |
| Apr 8, 2026 | Camblong Jurgi | Chief Executive Officer | SELL | 2,800 | $4.84 | $13.6K |
| Apr 8, 2026 | Muken Ross | President | SELL | 2,786 | $4.84 | $13.5K |
| Apr 8, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 2,800 | $4.84 | $13.5K |
| Apr 8, 2026 | Menu Philippe | Chief Medical Officer | SELL | 2,800 | $4.84 | $13.5K |
| Apr 8, 2026 | Valente Manuela | Chief People Officer | SELL | 3,824 | $4.85 | $18.5K |
| Apr 8, 2026 | Van Well Daan | Chief Legal Officer | SELL | 2,861 | $4.85 | $13.9K |
| Apr 7, 2026 | Verma Abhimanyu | Chief Technology Officer | SELL | 1,030 | $4.87 | $5.0K |
| Apr 7, 2026 | Xu Zhenyu | Chief Scientific Officer | SELL | 2,400 | $4.87 | $11.7K |
| Apr 7, 2026 | Valente Manuela | Chief People Officer | SELL | 2,376 | $4.87 | $11.6K |
14 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 1 mixed, 9 neutral. Avg impact: 4.1/10.
BULLISH
6-K
6/10
SOPHiA GENETICS announced a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer C
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Seven SOPHiA GENETICS insiders, including the CEO and C-suite, sold a total of $57K in open-market s
Jun 1, 2026
NEUTRAL
CLUSTER
2/10
Four SOPHiA GENETICS insiders sold a total of $77K in shares over a 7-day window, representing 0.023
May 20, 2026
NEUTRAL
6-K
2/10
SOPHiA GENETICS published its 2025 ESG Impact Summary, a routine annual disclosure of its environmen
May 19, 2026
NEUTRAL
6-K
4/10
SOPHiA GENETICS filed its 2026 Annual General Meeting proxy materials, including a CEO succession pl
May 8, 2026
MIXED
6-K
6/10
SOPHiA GENETICS reported Q1 2026 revenue of $21.7 million, up 22% YoY, driven by 16% growth in platf
May 5, 2026
BEARISH
CLUSTER
6/10
Multiple C-suite executives at SOPHiA GENETICS SA, including the CEO, sold shares in the open market
Apr 21, 2026
NEUTRAL
CLUSTER
3/10
Over the past 7 days, 8 insiders at SOPHiA GENETICS SA, including the CEO, CFO, and other C-suite ex
Apr 16, 2026
BEARISH
CLUSTER
5/10
Nine corporate insiders at SOPH, including the CEO, CFO, and other C-suite executives, sold shares i
Apr 14, 2026
NEUTRAL
CLUSTER
3/10
Nine corporate insiders at SOPH, including the CEO, CFO, and multiple C-suite executives, sold share
Apr 10, 2026
NEUTRAL
144
3/10
George Cardoza, an officer of SOPHiA GENETICS SA, filed a Form 144 to notify the SEC of his intent t
Apr 8, 2026
BEARISH
CLUSTER
7/10
A significant insider selling cluster at SOPH involves nearly all C-suite executives selling shares
Apr 8, 2026
NEUTRAL
CLUSTER
3/10
Three SOPHiA GENETICS executives — including the President, CFO, and Chief Sales Officer — sold shar
Mar 20, 2026
NEUTRAL
EFFECT
4/10
SOPHiA GENETICS SA has announced the effectiveness of a shelf registration (Form F-3) filed under SE
Mar 9, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.00 mean target
+60.0% upside
Strong Buy (3.00)
$7.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $5.00 |
| Target Low | $7.00 |
| Target Mean | $8.00 |
| Target Median | $8.00 |
| Target High | $9.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.22 | $-0.22 | $-0.22 | 10.5% | -4.8% | 1↑ 0↓ | $0.0B | 18.0% | 1 |
| Next Q 2026-09-30 |
$-0.19 | $-0.19 | $-0.19 | 3.4% | +0.0% | 1↑ 0↓ | $0.0B | 22.3% | 1 |
| Current FY 2026-12-31 |
$-0.78 | $-0.78 | $-0.78 | 1.7% | +2.5% | 1↑ 0↓ | $0.1B | 20.7% | 1 |
| Next FY 2027-12-31 |
$-0.56 | $-0.56 | $-0.56 | 28.2% | +0.0% | 1↑ 0↓ | $0.1B | 20.5% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.220 | |
| 7d ago | $-0.210 | -0.010 |
| 30d ago | $-0.210 | -0.010 |
| 60d ago | $-0.210 | -0.010 |
| 90d ago | $-0.230 | +0.010 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 15, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 5, 2026
earnings_calendar
SOPH Q1 2026 Earnings Scheduled — 2026-05-05
Mar 3, 2026
earnings_calendar
SOPH Q4 2025 Earnings After Market Close — 2026-03-03